Development and validation of a targeted affinity-enrichment and LC-MS/MS proteomics approach for the therapeutic monitoring of adalimumab.

摘要: Abstract Background The anti-tumor necrosis factor alpha (TNFα) therapeutic monoclonal antibodies (mAbs), such as adalimumab, are widely used in the treatment of rheumatoid arthritis, inflammatory bowel diseases, and other auto-immune diseases. administration adalimumab can elicit immune responses from some patients, resulting formation anti-drug (ADAbs). ADAbs diminish effects by neutralizing TNFα binding site or increasing its clearance circulation. Methods To effectively monitor concentrations we developed validated a targeted quantitative proteomic assay to determine circulating adalimumab. Since drug be attenuated ADAbs, method adopted an affinity-enrichment step selectively quantify bioavailable forms patient serum samples. Results performance LC–MS/MS based provides analytical measuring range precisions applicable for monitoring It also comparable results cell-based activity when evaluating samples with different Conclusion Our both sub-therapeutic This design alternative isotope-labeled peptides approach currently proteomics methods.